Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial

BACKGROUND: The treatment for ineligible transplant multiple myeloma is melphalan prednisone. Curcumin has an anti-inflammatory and antiangiogenesis in cancer-directed to nuclear factor-kappa B (NF-kB) pathway. Interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), tumor necrosis factor-al...

Descripción completa

Detalles Bibliográficos
Autores principales: Santosa, Damai, Suharti, Catharina, Riwanto, Ignatius, Dharmana, Edi, Pangarsa, Eko Adhi, Setiawan, Budi, Suyono, Suyono, Tobing, Mika Lumban, Suhartono, Suhartono, Hadisapurto, Soeharyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301229/
https://www.ncbi.nlm.nih.gov/pubmed/35919637
http://dx.doi.org/10.22088/cjim.13.2.9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301229/
https://www.ncbi.nlm.nih.gov/pubmed/35919637
http://dx.doi.org/10.22088/cjim.13.2.9

Ejemplares similares